Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)

Uwe Platzbecker, Rami S. Komrokji, Amer M. Zeidan, Pierre Fenaux, Mikkael A. Sekeres, Michael R. Savona, Yazan F. Madanat, Anna Jonášová, Thomas Illmer, Laurie Sherman, Tymara Berry, Jennifer Riggs, Qi Xia, Shyamala Navada, Ying Wan, Fei Huang, Faye M. Feller, Valeria Santini

Blood (2023) 142 (Supplement 1): 4605.

https://doi.org/10.1182/blood-2023-181154

Published: 2023

Journal Articles

Molecular Mechanisms Underlying Abnormal Activation of T Cells in Idiopathic Aplastic Anemia and Hypoplastic Myelodysplastic Neoplasms

Zuzana Lenertová, Monika Kaisrlikova, David Kundrat, Hana Votavova, Jitka Vesela, Iva Trsová, Sarka Ransdorfova, Iuri Marinov, Tomas Prochazka, Daniel Lysak, Anna Jonasova, Jaroslav Čermák, Monika Belickova

Blood (2023) 142 (Supplement 1): 1342.

https://doi.org/10.1182/blood-2023-181713

Published: 2023

Journal Articles

Different Mutations in SF3B1 Gene Have Specific Transcriptomic Characteristics in Myelodysplastic Neoplasms

Iva Trsová, Andrea Hrustincova, Monika Belickova, Monika Kaisrlikova, Zuzana Lenertová, David Kundrat, Zdenek Krejcik, Jitka Vesela, Jaroslav Cermak, Anna Jonasova, Michaela Dostalova Merkerova

Blood (2023) 142 (Supplement 1): 3218.

https://doi.org/10.1182/blood-2023-179068

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

Blood (2023) 142 (Supplement 1): 193.

https://doi.org/10.1182/blood-2023-178596

Published: 2023

Journal Articles

Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Amer M. Zeidan, Michael R. Savona, Yazan F. Madanat, Pierre Fenaux, Rami S. Komrokji, Anna Jonášová, Thomas Illmer, Libo Sun, Tymara Berry, Faye M. Feller, Shyamala Navada, Valeria Santini, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 6478.

https://doi.org/10.1182/blood-2023-180962

Published: 2023

Journal Articles

Accelerated Progression in Lower-Risk Myelodysplastic Neoplasms: Attenuated Cell Cycle, DNA Damage Response, and Augmented Oncogenic Transcriptome Signatures

Monika Kaisrlikova, Zuzana Lenertová, Pavla Koralkova, Iva Trsová, David Kundrat, Michaela Dostalova Merkerova, Hana Votavova, Zdenek Krejcik, Anna Jonasova, Jaroslav Cermak, Vladimir Divoky, Monika Belickova

Blood (2023) 142 (Supplement 1): 6454.

https://doi.org/10.1182/blood-2023-180496

Published: 2023

Journal Articles

First Single-Center Experience with Luspatercept Therapy in Low-Risk Myelodysplastic Syndrome (LR-MDS) Patients with Transfusion Dependence Refractory to Erythropoietin Therapy

Anna Jonasova, Lubomir Minarik, Zuzana Zemanova, Helena Polackova, Tomas Stopka

Blood (2022) 140 (Supplement 1): 12311–12312.

https://doi.org/10.1182/blood-2022-169270

Published: 2022

Journal Articles

Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial

Koichi Takahashi, Anna Jonasova, Selina M. Luger, Aref Al-Kali, David Valcarcel, Erica D. Warlick, Maria Diez-Campelo, Michael K Keng, Feng Wang, Ken Furudate, Patrick S. Zbyszewski, Matthew Parris, Steven M. Fruchtman, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 1517.

https://doi.org/10.1182/blood-2021-152048

Published: 2021

Journal Articles

A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139291

Published: 2020

Journal Articles

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis

Anna Jonasova, MD PhD, Lubomir Minarik, MD, Vojtech Kulvait, PhD, Michal Pesta, PhD, Adel Schaffartzikova, MD, Galina Kislik, PhD, Nina Dusilkova, MD, Zuzana Zemanova, PhD, Tomas Stopka, MD PhD

Blood (2019) 134 (Supplement_1): 1729.

https://doi.org/10.1182/blood-2019-124274

Published: 2019

Journal Articles

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Guillermo Garcia-Manero, MD, Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcárcel, MD, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Patrick S. Zbyszewski, MBA, Christopher Cavanaugh, Richard C. Woodman, MD, Steven M. Fruchtman, MD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 3015.

https://doi.org/10.1182/blood-2019-131632

Published: 2019

Journal Articles

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

Blood (2019) 134 (Supplement_1): 2998.

https://doi.org/10.1182/blood-2019-129047

Published: 2019

Journal Articles

RUNX1 Mutation Accompanied with Dysregulated Cellular Senescence in Lower-Risk Myelodysplastic Syndrome Patients Is Associated with Disease Progression

Monika Hruba, Jitka Vesela, Hana Votavova, PhD, Michaela Dostalova Merkerova, PhD MSc, David Kundrat, Katarina Szikszai, PhD, Marie Lauermanova, MD, Zuzana Zemanova, PhD, Anna Jonasova, MD PhD, Jaroslav Cermak, MD PhD, Monika Belickova, PhD

Blood (2019) 134 (Supplement_1): 4230.

https://doi.org/10.1182/blood-2019-131150

Published: 2019

Journal Articles

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcarcel, Richard C. Woodman, MD, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Matthew Parris, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4249.

https://doi.org/10.1182/blood-2019-132127

Published: 2019

Journal Articles

Relationship between Altered Gene Expression and DNA Methylation of the DLK1-DIO3 region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes

Michaela Dostalova Merkerova, PhD MSc, Hana Remesova, Zdenek Krejcik, Nikoleta Loudova, Andrea Hrustincova, Katarina Szikszai, PhD, Jitka Vesela, MSc, Jaroslav Cermak, MD PhD, Anna Jonasova, MD, Monika Belickova, PhD

Blood (2018) 132 (Supplement 1): 5496.

https://doi.org/10.1182/blood-2018-99-113378

Published: 2018

Journal Articles

Deregulated Expression of Long Noncoding RNAs H19 , LEF1-AS1 , TCL6, and WT1-AS1 Predicts Poor Outcome of Patients with Myelodysplastic Syndromes

Michaela Dostalova Merkerova, PhD MSc, Nikoleta Loudova, Katarina Szikszai, PhD, Zdenek Krejcik, Jiri Klema, Pavla Pecherkova, Andrea Hrustincova, Jitka Vesela, MSc, Jaroslav Cermak, MD PhD, Anna Jonasova, MD, Monika Belickova, PhD

Blood (2018) 132 (Supplement 1): 5498.

https://doi.org/10.1182/blood-2018-99-116071

Published: 2018

Journal Articles

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Lubomir Minarik, MD, Leylah M. Drusbosky, PhD, Taher Abbasi, MS, MBA, Karina Vargova, MBBS, MSc, Vojtech Kulvait, PhD, Anna Jonasova, MD, Neeraj Kumar Singh, B.Tech, Chandan Kumar, M.Tech, Rakhi Purushothaman Suseela, B.Tech, Mamatha Patil, B.E, Patil Nilesh Dattatraya, M.Sc., Krishna Kumar Tiwari, B.Tech, Shireen Vali, PhD, Christopher R. Cogle, MD, Tomas Stopka, MD PhD

Blood (2018) 132 (Supplement 1): 5506.

https://doi.org/10.1182/blood-2018-99-114466

Published: 2018

Journal Articles

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Radka Bokorová, MSc, Jaroslav Polak, MSc, Anna Jonasova, MD, Radana Neuwirtova, MD PhD, Marie Lauermannova, MD, Jaroslav Cermak, MD PhD, Marketa Stastna, MD PhD, Cyril Salek, Dana Mikulenkova, MD, Zuzana Zemanova, PhD, Jana Brezinova, Kyra Michalova, PhD, Denisa Myslivcova, PhD, Ota Fuchs, PhD

Blood (2018) 132 (Supplement 1): 5507.

https://doi.org/10.1182/blood-2018-99-115803

Published: 2018

Journal Articles

Mutations in RUNX1 and TP53 Genes Predict Progression in Patients with Lower-Risk Myelodysplastic Syndrome

Monika Hruba, MSc, Jitka Vesela, MSc, Hana Votavova, PhD, Michaela Dostalova Merkerova, PhD MSc, Katarina Szikszai, PhD, Marie Lauermannova, MD, Zuzana Zemanova, PhD, Anna Jonasova, MD, Jaroslav Cermak, MD PhD, Monika Belickova, PhD

Blood (2018) 132 (Supplement 1): 5519.

https://doi.org/10.1182/blood-2018-99-118048

Published: 2018

Journal Articles

Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacytidine (Data from Czech MDS Group)

Zuzana Zemanova, PhD, Kyra Michalova, PhD, Karla Svobodova, Jana Brezinova, Halka Lhotska, PhD, Libuse Lizcova, PhD, Iveta Sarova, PhD, Silvia Izakova, Lucie Hodanova, PhD, Denisa Vesela, Sarka Ransdorfova, Monika Belickova, PhD, Jitka Vesela, MSc, Helena Polackova, Magda Siskova, MD, Radana Neuwirtova, MD PhD, Jaroslav Cermak, MD PhD, Tomas Stopka, MD PhD, Anna Jonasova, MD

Blood (2018) 132 (Supplement 1): 1815.

https://doi.org/10.1182/blood-2018-99-114151

Published: 2018

NARROW

Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)

Molecular Mechanisms Underlying Abnormal Activation of T Cells in Idiopathic Aplastic Anemia and Hypoplastic Myelodysplastic Neoplasms

Different Mutations in SF3B1 Gene Have Specific Transcriptomic Characteristics in Myelodysplastic Neoplasms

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Accelerated Progression in Lower-Risk Myelodysplastic Neoplasms: Attenuated Cell Cycle, DNA Damage Response, and Augmented Oncogenic Transcriptome Signatures

First Single-Center Experience with Luspatercept Therapy in Low-Risk Myelodysplastic Syndrome (LR-MDS) Patients with Transfusion Dependence Refractory to Erythropoietin Therapy

Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial

A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

RUNX1 Mutation Accompanied with Dysregulated Cellular Senescence in Lower-Risk Myelodysplastic Syndrome Patients Is Associated with Disease Progression

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Relationship between Altered Gene Expression and DNA Methylation of the DLK1-DIO3 region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes

Deregulated Expression of Long Noncoding RNAs H19 , LEF1-AS1 , TCL6, and WT1-AS1 Predicts Poor Outcome of Patients with Myelodysplastic Syndromes

Mechanisms of Azacitidine Chemotherapy Resistance in AML and MDS and New Therapy Options

Importance of Transcription Factor Nrf2 for Cereblon Expression and Clinical Response to Combination of Lenalidomide and Erythropoietin in Lower-Risk Myelodysplastic Syndromes

Mutations in RUNX1 and TP53 Genes Predict Progression in Patients with Lower-Risk Myelodysplastic Syndrome

Chromothripsis in High-Risk Myelodysplastic Syndromes: Incidence, Genetic Features, Clinical Implications, and Impact on Survival of Patients Treated with Azacytidine (Data from Czech MDS Group)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only